Ending cancer. Together.

Size: px
Start display at page:

Download "Ending cancer. Together."

Transcription

1 Ending cancer. Together.

2 Making History by Being First To achieve something as big and bold as ending cancer requires the courage to be first and a willingness to partner with others. At the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, we have brought bold ideas to our research on using the body s immune system to fight cancer. Being housed under one roof has fostered the ability of our bench scientists and physicians at the bedside to work together, developing the best new ideas to improve cancer treatment. Our patients have often been the first in the world to receive a new cancer immunotherapy treatment. That takes courage, particularly on the part of our patients. It also takes determination on behalf of our team to partner with others who aspire to be bold with us. Here is a glimpse of our track record of firsts: First in the world n Genetically modified patient-derived tumor vaccine coupled with adoptive T cell transfer and interleukin-2 (IL-2) to treat late-stage melanoma (1995) n IL-21 for melanoma and renal cancer (2004) n Combination immunotherapy with chemotherapy, adoptive T cell transfer and vaccination for prostate cancer (2005) n Anti-OX40 for patients with advanced cancer (2006) n Patient-derived DRibble lung cancer vaccine (2009) n Stereotactic body radiotherapy (SBRT) plus IL-2 to treat late-stage melanoma and renal cancer (2009) n Off-the-shelf DRibble vaccine in lung cancer (2013) n Anti-PD-1 plus anti-kir to treat melanoma (2013) n Genetically modified listeria vaccine to treat glioblastoma brain cancer (2014) First in Oregon n Adoptive immunotherapy and high-dose IL-2 to treat late-stage melanoma (1994) n High-dose IL-2 to treat late-stage melanoma and renal cancer (1997) n Genetically modified breast cancer vaccine (1997) n Sipuleucel-T (Provenge) to treat prostate cancer (2000) n Ipilimumab to treat late-stage melanoma (2003) n Sorafenib to treat advanced kidney cancer (2004) n Anti-PD-1 to treat melanoma (2012) We are also the only cancer center on the West Coast to become part of Bristol-Myers Squibb s International Immuno-Oncology Network (2012). Our team is ready to make many more firsts, but we need your help. Join Center of Hope: For more information, contact Shari Lynn Scales, CFRE at or

3 Center of Hope: 2017 Ending Cancer. Together. Providence wants to help end cancer. Since the founding of our research program in 1993, we have made incredible progress bringing life-saving discoveries, such as anti-ox40, to patients and having the scientific world recognize immunotherapy as the newest standard of treatment for cancer. Yet we are called to do more. We are enlisting the support of visionary people through an initiative called Center of Hope: This initiative seeks to raise $65 million to enhance our established track record of innovation and discovery. I was absolutely at the right place. There is no doubt in my mind that Providence Cancer Center has world-class doctors, researchers, nurses and staff. I know I wouldn t be here today without them. Mark Williams was diagnosed with metastatic melanoma in Thanks to immunotherapy supported by philanthropy, Mark is tumor-free today. At Providence, science and medicine have joined together to study and understand the equation of how our body s immune system can fight cancer. Our focused research spanning more than two decades contributed to cancer immunotherapy being named as Science journal s Breakthrough of the Year in In spite of the advances made, one-third of all patients diagnosed with cancer still die of their disease (more than half a million Americans each year). They can t wait another decade or even another year. We must grasp this moment in history to continue developing immunotherapy and to continue our commitment of caring for the whole person.

4 Why Providence Cancer Center? n For years, our scientists have recognized the key role that the immune system plays in eliminating cancer cells. Now it is a proven fact that immunotherapy improves survival for cancer patients. n Walter J. Urba, M.D., Ph.D., came to Providence from the National Cancer Institute in 1993 believing that the immune system plays a role in recognizing and eliminating cancer. He, along with Bernard Fox, Ph.D., has led a team of investigators exclusively focused on tumor immunology at the Earle A. Chiles Research Institute. n Dr. Urba served as senior author and principal investigator on the international trial that led to the first immunotherapy drug approved for patients with melanoma ipilimumab. This was the first therapy to improve survival of patients with melanoma. And, its approval by the FDA was a watershed moment and an important milestone for the oncology community. This achievement was key to cancer immunotherapy being named Science journal s Breakthrough of the Year for n Andrew Weinberg, Ph.D., discovered anti-ox40 and with Brendan Curti, M.D., performed a clinical trial that demonstrated the safety and potential efficacy of anti-ox40. This led to the formation of AgonOx, a Providence-derived biotechnology company, and eventual partnership with the global pharmaceutical company, AstraZeneca. This discovery resulted from an innovative collaboration between bench scientists, clinical investigators and the philanthropic community. Clinical trials continue to define the value of anti-ox40, and a strategy to get anti-ox40 to market has been developed. n Providence Cancer Center is one of 11 leading research institutions in the world, and the only U.S. site west of the Mississippi River, selected by Bristol-Myers Squibb to form the International Immuno-Oncology Network. n We are one of 26 cancer centers across the country with the Cancer Immunotherapy Trials Network (CITN) designation a National Cancer Institute meritocracy. CITN employs the collective expertise of top academic immunologists to design and conduct cancer therapy trials with the most promising immunotherapy agents prioritized for high potential in treating cancer. This work is done in collaboration with the National Cancer Institute and other academic and industry partners. n We have a proven track record for investigator-initiated clinical trials. In addition to ipilimumab and anti-ox40, we have initiated first-in-human trials for a novel, bacterial-based vaccine for glioblastoma multiforme (brain cancer); alpha-tea, a vitamin E analog proven effective on breast cancer in pre-clinical models; and combination stereotactic body radiation therapy with immunotherapy for patients with advanced metastatic melanoma.

5 What will $65 million provide? n More translational research. With more research will come more breakthroughs in cancer immunotherapy at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute. n A larger team of investigators. The success of our efforts will only be as good as the people chosen to lead our work. n Laboratory expansion. Financial support will allow us to finish 7,000 square feet of shelled space in the Earle A. Chiles Research Institute in Providence Cancer Center. n Improved patient support and outreach. Our patient advocates, nurse navigators, survivorship team, oncology palliative care and integrative medicine services greatly improve the quality of life for cancer patients and their families. n Endowment. High-level funding will ensure sustainability by securing the future of world-class research and state-of-the-art cancer care through endowed chairs and funding to allow engagement in research activities. Philanthropy allows us to Bring promising research and support to patients faster. How you can help end cancer n Give. Make a gift or pledge to Providence Cancer Center. n Get involved. Take a tour, meet our research team in person or attend a gathering. n Introduce. Share information about our work with others; host tours or gatherings for your friends. n Remember. Remember Providence in your will or estate plan to shore up the future of cancer research, treatment and care. For more information, contact Shari Lynn Scales at or Ending cancer. Together Providence Cancer Center MILESTonES Mother Joseph of the Sacred Heart and four other Sisters of Providence arrived in Vancouver, Washington Territory. The Earle A. Chiles Research Institute at Providence Portland Medical Center is dedicated. Walter J. Urba, M.D., Ph.D., is recruited from the National Cancer Institute to start a cancer research program at the Earle A. Chiles Research Institute. OX40 research begins at Providence Cancer Center. A leadership gift names the Robert W. Franz Cancer Research Center. First high-dose IL-2 patient in the world is treated at Providence Cancer Center. First patient in the world receives anti-ox40 at Providence Cancer Center. Providence Together campaign raises $74 million. Providence Cancer Center opens a new 200,000 square-foot facility with all cancer services under one roof. First patient in the world is treated with IL-2 and SBRT combination therapy. MedImmune, a division of AstraZeneca, signs an agreement with Providence Cancer Center to further develop anti-ox The journal Science names cancer immunotherapy as the Breakthrough of the Year.

6 OUR MISSION As people of Providence, we reveal God s love for all, especially the poor and vulnerable, through our compassionate service. OUR CORE VALUES Respect, Compassion, Justice, Excellence, Stewardship Providence Health & Services, a not-for-profit health system, is an equal opportunity organization in the provision of health care services and employment opportunities. OR SAB 5-14

A comprehensive treatment and research center for people with brain tumors

A comprehensive treatment and research center for people with brain tumors Brain Tumor Center A comprehensive treatment and research center for people with brain tumors UC Brain Tumor Center Our Collaborative Team The medical and surgical management of brain tumors requires a

More information

We want to keep prostate cancer from coming back. We re looking for 711 men who want to help.

We want to keep prostate cancer from coming back. We re looking for 711 men who want to help. We want to keep prostate cancer from coming back. We re looking for 711 men who want to help. IMPORTANT INFORMATION FOR PROSTATE CANCER PATIENTS The odds are already in your favor. If you have been diagnosed

More information

Immunotherapy of Uveal Melanoma

Immunotherapy of Uveal Melanoma Eye Am Not Alone (EANA) Patient Retreat Saturday Session - March 3, 2012 Immunotherapy of Uveal Melanoma Do not distribute or copy without the express permission of the Ocular Melanoma Foundation (OMF).

More information

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

More information

Thank you to our webinar sponsors:

Thank you to our webinar sponsors: Treatment Approaches for Pancreatic Cancer January 27, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

CANCER CENTER SERVICES GUIDE

CANCER CENTER SERVICES GUIDE CANCER CENTER SERVICES GUIDE A Place of Hope and Healing Since 1999, The Robert and Carol Weissman Cancer Center at Martin Health has combined medical expertise with advanced technology and access to clinical

More information

Your Immune System & Cancer Treatment

Your Immune System & Cancer Treatment Your Immune System & Cancer Treatment Immunotherapy Today, immunotherapy is one of the most exciting areas of new discoveries and treatments for many different kinds of cancer. Researchers now know that

More information

Metastatic Melanoma What You Need to Know

Metastatic Melanoma What You Need to Know ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients

More information

4 PROVIDENCE TOGETHER. www.providence.org/together

4 PROVIDENCE TOGETHER. www.providence.org/together 4 PROVIDENCE TOGETHER www.providence.org/together ancer entered Clara Harris life early. Her mother died When surgery is a risky option, cancer patients such as Clara Harris are benefiting from a new and

More information

I give so that new treatments can be found

I give so that new treatments can be found I give so that new treatments can be found By giving, you gain the power to advance research and patient care. Help us reach the goal of our first multiple myeloma fundraising campaign! $2 million The

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

National Framework for Excellence in

National Framework for Excellence in National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

Cancer Services for Adults and Children

Cancer Services for Adults and Children UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer

More information

Probe: Could you tell me about when?

Probe: Could you tell me about when? PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Northwestern Brain Tumor Institute

Northwestern Brain Tumor Institute Northwestern Brain Tumor Institute PATIENT AND VISITOR GUIDE TO THE NORTHWESTERN MEDICAL CAMPUS Chicago Avenue Lake Shore Drive Prentice Women s Hospital Superior Street Michigan Avenue St. Clair Street

More information

CAMPAIGN: Transforming MEDICINE Beyond IMAGINATION

CAMPAIGN: Transforming MEDICINE Beyond IMAGINATION Our CAMPAIGN: Transforming MEDICINE Beyond IMAGINATION The School of Medicine Research Building: Health Sciences Facility III A MESSAGE from DEAN REECE Consider for a moment this question what shapes the

More information

HOAG FAMILY CANCER INSTITUTE. Case for Support

HOAG FAMILY CANCER INSTITUTE. Case for Support HOAG FAMILY CANCER INSTITUTE Case for Support HOAG FAMILY CANCER INSTITUTE KEEPING THE PROMISE OF HOAG FAMILY CANCER INSTITUTE Dr. Eisenberg and his team of renowned physicians meet regularly to discuss

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor

More information

Biological Therapies for Cancer

Biological Therapies for Cancer Biological Therapies for Cancer Key Points Biological therapies use the body's immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapies

More information

The Center for Cancer Care. Comprehensive and compassionate care

The Center for Cancer Care. Comprehensive and compassionate care The Center for Cancer Care Comprehensive and compassionate care Welcome to the Center for Cancer Care The Center for Cancer Care at Exeter Hospital provides comprehensive, compassionate care for a wide

More information

Understanding Clinical Trials: A Guide for Patients and Caregivers

Understanding Clinical Trials: A Guide for Patients and Caregivers Understanding Clinical Trials: A Guide for Patients and Caregivers Being aware of clinical trials is important. Clinical trials drive progress in cancer treatment and care. Clinical trials may provide

More information

OVERLAKE CANCER CENTER CAMPAIGN TO CREATE MOST ADVANCED & THE COMPREHENSIVE CANCER CENTER FOR THE EASTSIDE COMMUNITY

OVERLAKE CANCER CENTER CAMPAIGN TO CREATE MOST ADVANCED & THE COMPREHENSIVE CANCER CENTER FOR THE EASTSIDE COMMUNITY OVERLAKE CANCER CENTER CAMPAIGN TO CREATE THE MOST ADVANCED & COMPREHENSIVE CANCER CENTER FOR THE EASTSIDE COMMUNITY WHY WE RE BUILDING A NEW CANCER CENTER The story of cancer treatment is changing. On

More information

Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments

Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments The Core Problem One Symptom, Not One Disease The disease we call cancer is the second most common cause of death in the United

More information

A Proposal to fund the Irene Thompson Byrd Cancer Care Endowment to benefit Patients of the Cape Fear Valley Cancer Treatment and CyberKnife Center

A Proposal to fund the Irene Thompson Byrd Cancer Care Endowment to benefit Patients of the Cape Fear Valley Cancer Treatment and CyberKnife Center purpose. passion. precision. A Proposal to fund the Irene Thompson Byrd Cancer Care Endowment to benefit Patients of the Cape Fear Valley Cancer Treatment and CyberKnife Center cancer treatment and cyberknife

More information

R508 A NEW NON-TOXIC DRUG TREATMENT THAT KILLS CANCER

R508 A NEW NON-TOXIC DRUG TREATMENT THAT KILLS CANCER WE NEED YOUR HELP TESTING R508 A NEW NON-TOXIC DRUG TREATMENT THAT KILLS CANCER WE NEED $25,000 FOR CURRENT TESTING OF THIS POWERFUL NEW CANCER TREATMENT TABLE OF CONTENTS WHAT YOU NEED TO KNOW ABOUT R508

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

1in3 WHAT WE DO. Our vision is to bring forward the day when all cancers are cured.

1in3 WHAT WE DO. Our vision is to bring forward the day when all cancers are cured. cruk.org WHAT WE DO Our vision is to bring forward the day when all cancers are cured. Thousands of people are alive today thanks to research. Animal studies have played an important part in this progress.

More information

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not

More information

Academic Medicine: Where Patients Turn for Hope

Academic Medicine: Where Patients Turn for Hope Academic Medicine: Where Patients Turn for Hope Association of American Medical Colleges What Is Academic Medicine? Medical education research patient care. These three missions are the core of academic

More information

THE CENTRE FOR PHARMACEUTICAL ONCOLOGY

THE CENTRE FOR PHARMACEUTICAL ONCOLOGY THE CENTRE FOR PHARMACEUTICAL ONCOLOGY Application for Membership Send Completed Form to: sam.dalfonso@utoronto.ca Name (Last, First): Current Position: o Professor o Associate Professor o Assistant Professor

More information

The Brain and Spine CenTer

The Brain and Spine CenTer The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas

More information

CONQUERING CANCER SAVING LIVES. Mayo Clinic Proton Beam Therapy Program

CONQUERING CANCER SAVING LIVES. Mayo Clinic Proton Beam Therapy Program CONQUERING CANCER SAVING LIVES Mayo Clinic Proton Beam Therapy Program A MALIGNANT TUMOR IS A TYRANT Cancer takes all the body s resources for itself invading and displacing surrounding tissues. Abolishing

More information

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer

More information

Level 1. Nutrition & Lifestyle Oncology Certificate

Level 1. Nutrition & Lifestyle Oncology Certificate Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps

More information

Providence Telemedicine Network

Providence Telemedicine Network Providence Telemedicine Network Around the clock, around the region, our specialists are with you when every minute counts. Telemedicine brings our specialists to your hospital It is exciting to report

More information

immunotherapy a guide for the patient

immunotherapy a guide for the patient immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Monoclonal Antibodies... 6 Vaccines... 7 Adoptive T-Cell Transfer... 8 Oncolytic Viruses...

More information

Your Immune System & Lung Cancer Treatment

Your Immune System & Lung Cancer Treatment Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy

More information

Giving Back Lives...

Giving Back Lives... Center for Drug & Alcohol Programs Giving Back Lives... through World-Class Research Education Patient Care Outreach CDAP is Giving Back Lives Mission Statement Our mission is to use state-of-the-art research

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

Immune Therapy for Pancreatic Cancer

Immune Therapy for Pancreatic Cancer Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:

More information

Center for Drug & Alcohol Programs

Center for Drug & Alcohol Programs Center for Drug & Alcohol Programs Changing What s Possible... through World-Class Research Education Patient Care Outreach CDAP is Changing What s Possible Mission To combat alcoholism and drug addiction

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

CANCER LEADERSHIP COUNCIL

CANCER LEADERSHIP COUNCIL CANCER LEADERSHIP COUNCIL A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS ADDRESSING PUBLIC POLICY ISSUES IN CANCER March 27, 2015 The Honorable Fred Upton Chairman, Committee on Energy & Commerce

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Fundraising and Research Objectives

Fundraising and Research Objectives THE EHE FOUNDATION THE EHE RARE CANCER CHARITY (UK)* THE EHE RARE CANCER FOUNDATION (AUSTRALIA)* Fundraising and Research Objectives Thank you for taking the time to find and engage with our Fundraising

More information

VISION STATEMENT. Guiding principles:

VISION STATEMENT. Guiding principles: VISION STATEMENT Overview The University of Nevada, Las Vegas (UNLV) School of Medicine will address the well-identified need to further advance healthcare in Southern Nevada and establish the foundation

More information

clinical trials patient-assisted research studies

clinical trials patient-assisted research studies LUNG CANCER TREATMENTS What you need to know about... clinical trials patient-assisted research studies foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

UNCLASSIFIED STATEMENT BY

UNCLASSIFIED STATEMENT BY UNCLASSIFIED FINAL STATEMENT BY CAROLYN J.M. BEST, PhD PROGRAM MANAGER OF THE PROSTATE CANCER RESEARCH PROGRAM OF THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OF THE UNITED STATES ARMY MEDICAL

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

TAKING PART IN CANCER TREATMENT RESEARCH STUDIES

TAKING PART IN CANCER TREATMENT RESEARCH STUDIES For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer

More information

North Central Cancer Treatment Group

North Central Cancer Treatment Group North Central Cancer Treatment Group Working with Mayo Clinic to Bring the Latest Cancer Treatment to the Community NCCTG Dedicated to you More than 1.3 million people in the United States will be diagnosed

More information

A guide for the patient

A guide for the patient Understanding series LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS The Basics What is a Clinical Trial?...3 Types of Clinical Trials... 3 Phases

More information

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology

More information

Clinical Trials: Improving the Care of People Living With Cancer

Clinical Trials: Improving the Care of People Living With Cancer CLINICAL TRIALS Clinical Trials: Improving the Care of People Living With Cancer Presented by Mary McCabe, RN, MA Memorial Sloan-Kettering Cancer Center Carolyn Messner, DSW CancerCare Learn about: Stages

More information

RADIATION THERAPY FOR BRAIN METASTASES. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

RADIATION THERAPY FOR BRAIN METASTASES. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY RADIATION THERAPY FOR BRAIN METASTASES Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT BRAIN METASTASIS Brain metastases are clusters

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Committee on Oversight and Government Reform Domestic Policy Subcommittee U.S. House of

More information

Investing in the School of Medicine

Investing in the School of Medicine Investing in the School of Medicine The WVU School of Medicine: West Virginia s Greatest Force for Health At a crucial moment in each generation, the people who care most about West Virginia and West

More information

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated

More information

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its

More information

Academic Drug Development: Bench to First in Man Without Industry. Elizabeth M. Jaffee, M.D. The Dana and Albert Cubby Professor of Oncology

Academic Drug Development: Bench to First in Man Without Industry. Elizabeth M. Jaffee, M.D. The Dana and Albert Cubby Professor of Oncology Academic Drug Development: Bench to First in Man Without Industry Elizabeth M. Jaffee, M.D. The Dana and Albert Cubby Professor of Oncology Conflict of Interest Statement Under a licensing agreement between

More information

Resumen Curricular de los Profesores. Jesse Boehm

Resumen Curricular de los Profesores. Jesse Boehm Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub

More information

Immunovaccine Inc. (TSX-V: IMV) July 2011

Immunovaccine Inc. (TSX-V: IMV) July 2011 Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities

More information

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:

More information

365 days of dedication to ending childhood cancer and other life-threatening diseases.

365 days of dedication to ending childhood cancer and other life-threatening diseases. P A R T N E R I M P A C T R E P O R T 2 0 1 6 365 days of dedication to ending childhood cancer and other life-threatening diseases. For everything that you have accomplished for St. Jude, we want to say

More information

Role of clinical trials in professional development

Role of clinical trials in professional development Role of clinical trials in professional development Peeter Padrik Tartu University Hospital University of Tartu Estonian Society for Medical Oncology How we do treatment decisions? Personal experience?

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Systematic Drug Repurposing: Some Successes, Caveats, and Directions

Systematic Drug Repurposing: Some Successes, Caveats, and Directions Systematic Drug Repurposing: Some Successes, Caveats, and Directions Christopher P. Austin, M.D. Director, Division of Preclinical Innovation National Center for Advancing Translational Sciences National

More information

2014 ANNUAL REPORT. Transforming CANCER CARE. through service, science and partnership

2014 ANNUAL REPORT. Transforming CANCER CARE. through service, science and partnership 2014 ANNUAL REPORT Transforming CANCER CARE through service, science and partnership MISSION Moffitt s mission is to contribute to the prevention and cure of cancer. VISION Our vision is to transform cancer

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Clinical Trials. Helpful information and answers for patients

Clinical Trials. Helpful information and answers for patients Clinical Trials Helpful information and answers for patients I joined a clinical trial because I want to make it a better world for my daughter and grandchildren. Hopefully, by the time they re old enough

More information

the good samaritan society

the good samaritan society Give Well. Live Well. the good samaritan society m j j why do people give to the health first foundation? Health First is a locally operated community asset functioning as a not-for-profit network of hospitals,

More information

Susan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer. Judith A. Salerno, M.D., M.S. President and Chief Executive Officer

Susan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer. Judith A. Salerno, M.D., M.S. President and Chief Executive Officer Susan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer Judith A. Salerno, M.D., M.S. President and Chief Executive Officer Summer 2014 Who We Are: Executive Summary In just 32 years,

More information

Your giving made a difference in FY 2016

Your giving made a difference in FY 2016 HOAG IRVINE Your giving made a difference in FY 2016 The opening of Hoag Hospital Irvine in 2010 was a historic landmark in expanding access to the Hoag experience. Now, six years later, we continue our

More information

Clinical Trials: The Crux of Cancer Innovation

Clinical Trials: The Crux of Cancer Innovation Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded

More information

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

Inova. Breast Care Institute

Inova. Breast Care Institute Inova Breast Care Institute At the Inova Breast Care Institute, our commitment is to provide expert care for you, every step of the way. Our multidisciplinary team of more than 80 experts provides a full

More information

Navigating Malignant Melanoma: A Unique Physician, Nurse, and Patient Seminar Series

Navigating Malignant Melanoma: A Unique Physician, Nurse, and Patient Seminar Series Jointly sponsored/coprovided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in association with Navigating Malignant Melanoma: A Unique Physician, Nurse, and Patient

More information

Bristol Hospital Cancer Care Center 2015 Annual Report

Bristol Hospital Cancer Care Center 2015 Annual Report Bristol Hospital Cancer Care Center 2015 Annual Report 2015 Annual Report Cancer Care Center At every point along the path, our team is there, keeping the focus on the most important team member - the

More information

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio 10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving

More information

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced

More information

International Services

International Services International Services Consistently ranked as one of the best hospitals in the United States by U.S.News & World Report, patients from around the world travel to UCSF Medical Center and UCSF Benioff Children

More information

The Skin Deep research that saves lives. Creating Hope

The Skin Deep research that saves lives. Creating Hope Skin Cancer Research Institute The Skin Deep research that saves lives Creating Hope Through Discovery From Cover: Immune cells (shown in pink and green) try to control the growth of a group of skin cells

More information

cystic fibrosis (CF) in the United States, we are pleased to submit the following testimony to the

cystic fibrosis (CF) in the United States, we are pleased to submit the following testimony to the Robert J. Beall, Ph.D. Cystic Fibrosis Foundation President and Chief Executive Officer On behalf of the Cystic Fibrosis Foundation and the approximately 30,000 people with cystic fibrosis (CF) in the

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Clinical Trials. Cancer Care. Well Respected. Well Connected ṢM. More answers to beat cancer.

Clinical Trials. Cancer Care. Well Respected. Well Connected ṢM. More answers to beat cancer. Clinical Trials More answers to beat cancer. Cancer Care Well Respected. Well Connected ṢM Clinical research means more options and new hope. Ingalls Cancer Care connects patients to more options. Ingalls

More information

Researching Cancer Medicines: Setbacks and Stepping Stones

Researching Cancer Medicines: Setbacks and Stepping Stones Researching Cancer Medicines: Setbacks and Stepping Stones Researching Cancer Medicines: Setbacks and Stepping Stones 2 Executive Summary 3 Introduction 4 The Human Burden 5 The Economic Burden 6 Understanding

More information

Increasing Patient Access through Oral Parity Legislation

Increasing Patient Access through Oral Parity Legislation Increasing Patient Access through Oral Parity Legislation The Leukemia & Lymphoma Society A powerhouse among nonprofits searching for cancer cures Our Mission; Cure leukemia, lymphoma, Hodgkin s disease

More information

Equity markets Major advances in cancer therapeutics 18 August 2015

Equity markets Major advances in cancer therapeutics 18 August 2015 Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that

More information

The Role of Gene Therapy in Cancer Treatment. Rehan Mujahid. Abstract

The Role of Gene Therapy in Cancer Treatment. Rehan Mujahid. Abstract The Role of Gene Therapy in Cancer Treatment Rehan Mujahid Abstract Cancer is one of the major diseases in the world. This paper explores the biology of cancer cells and explains how they are originated.

More information

Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases

Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Jeff Gulcher, MD PhD Chief Scientific Officer and co-founder decode

More information